Dopamine and Norepinephrine in Shock Patients

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy of dopamine and norepinephrine, two commonly used vasopressor agents, in the treatment of shock.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sepsis Occurrence in Acutely Ill Patients
• Treatments: Dopamine; Dopamine Agents; Norepinephrine

Criteria

Inclusion Criteria:

• Mean arterial pressure less than 70 mmHg or systolic pressure less than 100 mmHg persisting despite adequate fluid loading (in example with at least 1000 mL crystalloid or 500 ml colloid) unless central venous pressure (CVP) or pulmonary artery occluded pressure (PAOP) are elevated (e.g. CVP> 12 mmHg or PAOP > 14 mmHg).

Exclusion Criteria:

• Serious arrhythmia such as rapid atrial fibrillation (> 160/min) or ventricular tachycardia.

• Brain death.

• Open label administration of dopamine, norepinephrine, epinephrine or phenylephrine for more than 4hours.